Answers are grounded in this paper and cite their sources.
Cirrhosis is characterized by immune dysfunction in which activated CD8⁺ T cells fuel systemic inflammation and disease progression. Non-selective beta-blockers (NSBB), widely prescribed for portal hypertension, have incompletely understood immunomodulatory effects. Here we show that CD8⁺ T cells express β2-adrenergic receptors, enriched in bystander relative to antigen-specific subsets. In vitro , the NSBB propranolol selectively suppressed cytokine-driven bystander activation, reducing CD69⁺CXCR6⁺ and NKG2D⁺ populations and pro-inflammatory cytokines, while preserving antigen-specific responses. Transcriptomic profiling after NSBB treatment revealed downregulation of interferon signaling pathway via STAT1. In paired blood and ascites samples from patients with decompensated cirrhosis (n = 31), NSBB therapy was associated with reduced bystander-activated CD8⁺ T cells. In a retrospective cohort (n = 624), NSBB therapy correlated with lower systemic and intrahepatic inflammation. These findings identify β-adrenergic blockade as a mechanism that restrains bystander CD8⁺ T cell responses without impairing antigen-specific immunity, supporting NSBB therapy as a strategy to mitigate inflammation and improve outcomes in cirrhosis.
No takes yet. Share an insight, caveat, or question.
Lietzau et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: